Стартап Claryx получил 3,5 млн долларов для внедрения геномного мониторинга инфекций в больницах

For more information on genomics, check out these articles: Claryx has emerged from stealth with funding and a genomic surveillance platform designed to help hospitals identify hidden transmission chains, trace infection sources, and intervene before outbreaks grow. Health care-associated infections (HAIs) remain one of health care's most persistent challenges. Although infection prevention teams have significantly reduced many device-associated infections over the past decade, outbreaks that span multiple units or originate from environmental reservoirs can remain undetected until they have already spread. New York-based startup Claryx is aiming to change that. The company officially emerged from stealth this week after announcing $3.5 million in preseed funding led by Outlander VC and introducing its genomic intelligence platform designed to help hospitals identify transmission events earlier and trace infections back to their likely source. Rather than relying solely on traditional surveillance methods that identify outbreaks after case counts increase, Claryx analyzes the genomes of confirmed patient infections and compares them with The company describes the approach as "building the hospital immune system," allowing infection preventionists to identify where transmission is occurring and intervene sooner. The need remains substantial. According to the One challenge, according to Claryx, is that conventional surveillance often detects outbreaks only after infection counts exceed expected baselines within individual units. Smaller transmission chains spread across multiple wards may never trigger those alerts, allowing outbreaks to continue unnoticed. The company was founded in 2025 by brothers Kurt and Dirk Hackenberger after a personal family experience with a health care-associated infection. Their grandmother developed a severe infection following what had been expected to be a routine hospital procedure, an event that ultimately inspired the company's mission to better understand where infections originate. "We believe preventable infections are a solvable problem," said Kurt Hackenberger, cofounder and CEO of Claryx. "Today, we can tell a hospital where an infection came from. We're building toward a future where it never had to happen in the first place." For infection prevention professionals, technologies that combine genomic sequencing with environmental surveillance represent a growing area of interest as hospitals continue to explore ways to move from reactive outbreak investigations to earlier detection and targeted intervention. While widespread adoption will ultimately depend on operational feasibility, cost, and real-world performance across diverse health systems, advances in genomic surveillance may offer additional tools to support existing infection prevention programs rather than replace them.